Stockscreener 앱 받기
3.94
2.34%
0.09
시장 영업 전:
3.94
전일 마감가:
$3.85
열려 있는:
$3.9
하루 거래량:
1.30M
Relative Volume:
4.56
시가총액:
$153.32M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-1.3972
EPS:
-2.82
순현금흐름:
$-35.26M
1주 성능:
-5.52%
1개월 성능:
-14.35%
6개월 성능:
+106.28%
1년 성능:
+29.18%
1일 변동 폭
$3.78
$4.07
1주일 범위
$3.78
$4.3784
52주 변동 폭
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.94 | 153.32M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
모두보기
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Protara Therapeutics Announces Appointment of Leonardo Viana Nic - GuruFocus
Scotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform Recommendation - Nasdaq
Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target - marketscreener.com
Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News - GuruFocus
Protara Therapeutics Names Leonardo Viana Nicacio CMO - MarketScreener
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - The Manila Times
Strategic Leadership Boost: Protara Gains 20-Year Oncology Expert as CMO Ahead of Key Trial Data - Stock Titan
Could Protara's ADVANCED-2 Trial Data Trigger A Stock Rally? - RTTNews
Protara Therapeutics to Present Interim Analysis from the Phase - GuruFocus
Commonwealth Equity Services LLC Has $195,000 Stock Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade - MSN
Protara to present bladder cancer trial data at AUA meeting - Investing.com Australia
Protara Therapeutics to Present Interim Analysis from the - GlobeNewswire
Critical Phase 2 Data Coming: TARA-002 Shows Promise in Treating Resistant Bladder Cancer - Stock Titan
Cantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight Recommendation - MSN
Protara Therapeutics officer sells shares worth $96,144 By Investing.com - Investing.com Australia
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (TARA) - Seeking Alpha
Protara Therapeutics officer sells shares worth $96,144 - Investing.com India
Cantor Fitzgerald Brokers Lower Earnings Estimates for TARA - Defense World
Cantor Fitzgerald Predicts TARA FY2025 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Protara reveals choline deficiency in parenteral support patients By Investing.com - Investing.com South Africa
Protara reveals choline deficiency in parenteral support patients - Investing.com
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - GlobeNewswire
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Cantor Fitzgerald - Defense World
Cantor Fitzgerald sets Overweight rating on Protara stock - Investing.com India
Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
Protara Therapeutics shares rise on narrower Q4 loss By Investing.com - Investing.com South Africa
Protara Therapeutics shares rise on narrower Q4 loss - Investing.com
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
자본화:
|
볼륨(24시간):